Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
- Merus also continues to evaluate patients with untreated advanced PD-L1+ HNSCC treated with petosemtamab 1500 mg in combination with pembrolizumab.
- Merus plans to report initial interim efficacy and safety data from this cohort in the second quarter of 2024.
- Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.
- Merus also achieved an additional milestone of $1 million for candidate nomination in the fourth quarter of 2023.